BSIM Therapeutics is awarded a US Patent

BSIM Therapeutics has been awarded a United States Patent (Patent #10,377,729) for one of its promising technologies in the stabilization of transthyretin (TTR) and with potential application in the treatment of TTR-mediated amyloidosis (ATTR).

With this and other technologies under development, BSIM therapeutics expects to raise to the challenge of answering to the unmet medical needs affecting patients with life-threatening TTR amyloidosis.